Sarepta Therapeutics (SRPT) PT Lowered to $75 at Needham & Company; 'FY17 Guidance Significantly Below Expectations'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Instinet Starts Sarepta Therapeutics (SRPT) at Buy, $84 PT
March 1, 2017 4:24 PM ESTInstinet initiates coverage on Sarepta Therapeutics (NASDAQ: SRPT) with a Buy rating and a price target of $84.00.
Analyst Christopher Marai commented, "We are initiating coverage on Sarepta Therapeutics (SRPT) with a Buy rating and $84 target price. We recommend owning SRPT shares, expecting significant... More
Sarepta Therapeutics (SRPT) Sees Strong Red-to-Green Reversal
March 1, 2017 11:17 AM ESTSarepta Therapeutics (NASDAQ: SRPT) reverses large after-hours losses and goes positive as CMS update adds pass-thru drug code C9484 or Eteplirsen. LINK
Shares are up 1.4%.
... More
